AcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program Key Opinion Leaders participating will be Stuart Goldstein, MD, Cincinnati Children’s Hospital and Lakhmir Chawla, MD, former Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center Webinar to be held Wednesday, May 4th at 1 pm EDT HAYWARD, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised s...
The independent financial analyst theScreener just requalified the general evaluation of ACELRX PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date November 30, 2021, the closing pric...
For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.